Cellectis S.A.
Status: Publicly traded
Direct answer
Cellectis S.A. is publicly traded on NASDAQ under the ticker CLLS.
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several...
Can you invest in Cellectis S.A.?
Yes. Cellectis S.A. is publicly traded on NASDAQ under the ticker CLLS.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Cellectis S.A.
Detailed equity research is provided by MarketSnap.